The stratification and survival impact of ACAs in CML. In cases with single ACAs, the types and frequencies of common ACAs were listed (A), and survival analysis following ACAs emergence (B) and CML diagnosis (C) was performed. In panel C, patients with no ACAs were included as a control. (D-E) Survival comparison between patients with 2 or more ACAs and patients with single ACAs. In patients with single ACAs, cases within each group were combined for survival analysis. Group 1 included patients with −Y, trisomy 8, and an extra Ph. Group 2 included patients with i(17), −7/Del(7q), and 3q26 rearrangements. Of note, survival analysis in this figure included all stages of disease (CP, AP, and BP).